Decreased PPARγ expression in UC patients has been shown [136], and the anti-inflammatory compound 5-aminosalicylic acid (5-ASA) commonly utilized in IBD therapy was shown to be a PPARγ agonist, thereby establishing a possible mechanism by which it exerts its anti-inflammatory effects [137]. The gene discussed is PPARG; the disease is inflammatory bowel disease.